The District of Delaware entered judgment in favor of MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limited on Novartis Pharmaceuticals Corporation’s action for infringement of a patent for Entresto, a tablet with active ingredients sacubitril and valsartan, used to treat heart failure. According to the court, Novartis didn’t prove that MSN’s ANDA infringes its patent by a preponderance of the evidence.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.